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Abstract
Introduction:  Connective tissue disorders can overlap in 
various ways. Patients may present with features of more 
than one specific disease without satisfying the diagnostic 
criteria and thereafter evolve into a specific disease 
entity. Occasionally, patients may fulfil simultaneously 
the diagnostic criteria of two or more diseases. Several 
cases of systemic sclerosis (SSc) and systemic lupus 
erythematosus (SLE) overlap syndrome have been 
reported. SLE patients often develop lupus nephritis, 
the treatment of which is based on immunosuppression 
with corticosteroids (CS) and cytotoxic drugs. However, 
the use of high dose of CS has been associated with 
scleroderma renal crisis (SRC) in patient with SSc. 
Case report: a 43-year-old woman presented to the 
nephrology department of the Military hospital in Rabat, 
Morocco, in August 2011 with progressive dyspnea and 
oliguria. She was diagnosed as SLE and scleroderma 
overlap syndrome based on clinical and serological 
markers. Renal biopsy showed lupus nephritis. 
Immunosuppression consisting of high-dose steroid and 
cyclophosphamide pulses was given. There was response 
to treatment but 15 days later the course of the disease 
was complicated by scleroderma renal crisis evidenced 
by elevated blood pressure, deteriorating kidney function, 
hemolysis and thrombocytopenia. The patient was 
treated with perindopril and rapid reduction of steroid 
doses. This was followed by correction of hemolysis and 
thrombocytopenia. Two months later, the patient was off 
dialysis, but had chronic renal insufficiency with an 
estimated GFR of 25 ml/minute.
Conclusion: This report describes the occurrence of 
SRC in a patient with lupus nephritis and SSc/
SLE overlap syndrome who was treated by CS and 
cyclophosphamide.
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Introduction
Connective tissue disorders can overlap in various 
ways. Patients may present with features of more than 
one specific disease without satisfying the diagnostic 
criteria and thereafter evolve into a specific disease 
entity. Occasionally, patients may fulfil simultaneously 
the diagnostic criteria of two or more diseases [1]. 
Several cases of systemic sclerosis (SSc) and systemic 
lupus erythematosus (SLE)  overlap syndrome have been 
reported [2, 3]. SLE patients often develop  lupus nephritis 
the treatment of which is based on immunosuppression 
with corticosteroids (CS) and cytotoxic drugs [4]. 
However the use of high doses of CS has been associated 
with scleroderma renal crisis (SRC) in patient with SSc [5]. 
This report describes the occurrence of SRC in a patient 
with lupus nephritis and SSc/SLE overlap syndrome who 
was treated by CS and cyclophosphamide.
Case report
A 43 year old woman presented to the nephrology 
department of the Military hospital in Rabat, Morocco, 
in August 2011 with progressive dyspnea and oliguria. 
She had no history of systemic disease like diabetes or 
hypertension and had not taken any medications. She 
had five pregnancies and five living children. She did 
not report any joint pain but had the typical complaints of 
Raynaud’s phenomenon. She had no fever or skin rash.
On admission, her blood pressure was 140/80 mmHg 
with a pulse rate of 70 beats/min. Clinical examination 
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She was consequently started on hemodialysis. The 
patient was treated with perindopril 10 mg/day with rapid 
reduction of steroid dose (10 mg every 15 days reaching 
a dose of 10 mg/day). This was followed by correction of 
hemolysis and thrombocytopenia. Two months later, the 
patient was weaned from dialysis, but had chronic renal 
insufficiency with an estimated GFR of  25 ml/minute 
according to the Modification of Diet in Renal Disease 
(MDRD) formula.
Discussion
Patients with connective tissue disorders can often be 
classified into a specific disease according to certain 
criteria. Occasionally, patients may have features 
of overlap between more than one disease. Overlap 
syndromes usually include polymyositis and either SLE 
or scleroderma. Coexistence of SLE with scleroderma is 
rare [1, 6]. In a large series of SSc patients who developed 
one or more additional autoimmune diseases, only (0.8%) 
of patient had coexistence of SLE [7]. Shared clinical 
features between scleroderma and SLE such as arthritis, 
Raynaud’s phenomena, and renal involvement complicate 
the definition of leading conditions and dictate the use of 
additional diagnostic tools [8].
In patients with overlap syndromes, autoantibody 
profiles might be useful in diagnosis, predicting response 
to treatment and long-term prognosis [9]. Interesting 
serological findings were present in this  case with 
positive anti-Scl-70, anti-dsDNA, and anti-RNP. High 
titers of anti-Scl-70 are highly specific for SSc but are 
present only in 10-15% of SSc patients. The average 
prevalence of anti-Scl-70 in SLE is less than 5%, and 
it’s observed only in low titers [10]. Anti-dsDNA and 
anti-Sm antibodies are present in 70 and 30% of SLE 
patients respectively [1]. Anti RNP is more frequent 
(44%) in SSC/SLE overlap syndrome [10]. Coexistence 
of these antibodies is really rare [11].
Approximately 5 to 10% of patients with scleroderma 
develop renal crisis that mimics malignant hypertension, 
with rapidly progressive renal failure secondary 
to microvascular disease, vasospasm and tissue 
ischemia. Microangiopathic hemolytic anemia and 
thrombocytopenia can accompany scleroderma renal 
crisis [12]. Renal crisis may also occur in asclerodermic 
scleroderma [13]. Studies demonstrate that high levels 
of serum renin levels are associated with vasospasm 
and intrinsic renal vessel disease [12]. Hypertension 
(> 140/90 mmHg) in a scleroderma patient should be 
carefully evaluated because renal crisis is potentially 
reversible with appropriate management with angiotensin 
converting enzyme (ACE) inhibitors. 
Histopathologically, there is concentric edematous intimal 
thickening of interlobular arteries and fibrinoid arteriolar 
necrosis causing elevation of plasma renin level with onset 
or aggravation of hypertension and rapid deterioration of 
renal function as a result of ischemic glomerulopathy. 
Variable changes may be seen in the glomeruli, in some 
cases thickening of glomerular capillary walls with a 
double contour appearance on silver or periodic acid-
Schiff staining may be seen. Fibrinoid  necrosis may 
also be seen [14]. Crescents are very rare and those seen 
are invariably small. Interlobular arteries show intimal 
thickening which is mucinous or finely fibrous. The 
thickening results in considerable reduction of the lumen 
[12]. The occurrence of this SRC may therefore be conf
-used with other microangiopathies secondary to lupus, 
particularly antiphospholipid syndrome.
Lupus nephritis is a major cause of morbidity and 
mortality in patients with SLE. The general consensus 
is that 45-86% of lupus patients will develop clinically 
relevant nephritis at some time in the course of   their illness 
[15]. The initial clinical presentation of lupus nephritis 
ranges from asymptomatic proteinuria discovered on 
routine urinalysis to the nephrotic syndrome with or 
without renal impairment. Histologic examination of a 
renal-biopsy specimen is a pivotal step in confirming the 
diagnosis and guiding therapy [16]. The histopathological 
patterns of lupus nephritis have been classified by the 
World Health Organization and, more recently, by the 
International Society of Nephrology/ Renal Pathology 
Society (ISN/RPS) [17]. Immunosuppressive therapy 
consists of glucocorticoids combined with a cytotoxic 
drug (cyclophosphamide, mycophenolate mofetil (MMF)) 
to achieve a prompt response [15]. In SSc/SLE patients 
who develop renal failure and hypertension, it is essential 
to distinguish between lupus nephritis and scleroderma 
renal crisis because the treatment is completely different 
[13]. Almost all current treatment regimens for lupus 
nephritis include steroids, usually pulses of high doses 
at induction and then tapering doses of oral steroids. 
However, SRC has been associated with the use of high 
doses or recently introduced corticoisteroids.
The concern that corticosteroid use may exacerbate the 
clinical manifestations of SSc has been longstanding 
[18]. A case control study retrospectively reviewed 
the relationship of SRC to corticosteroid use in the six 
months preceding the onset of SRC [19]. This study 
suggested that  recent  use of prednisone in dosages 
exceeding 15 mg daily was significantly associated with 
the subsequent onset of SRC, whereas recent use of 
low-dose steroids (less than 15 mg daily) or continuous 
use of steroids for six months was not associated with 
increased risk of SRC.
revealed pulmonary crackles and tightness of the 
skin over the face and hands. The rest of examination 
was normal.
Her urine dipstick examination revealed two crosses of 
protein and blood. 24-hour urine protein was 2 g/day. 
The blood urea and serum creatinine levels were 180 
mg/dL and 9.9 mg/dL respectively, sodium 137 meq/L 
and potassium  4.8 meq/L. Her complete blood count 
revealed a hemoglobin of 9 g/dl, a platelet count of 
272×109/L, and white blood cell count of 3000×109/L 
with 700×109/L lymphocytes. On admission she had 
no evidence of hemolysis with haptoglobin level of 1.6 
g/L, LDH 145 units/L, total bilirubin 0.5 mg/dL and 
alanine transaminase 10 units/L. Her serum albumin 
was 3.1 mg/dL. She was hepatitis B surface antigen and 
anti-HCV antibody negative.
Autoantibody screening at that time detected elevated 
titers of antinuclear antibodies (using indirect immu-
nofluorescence on HEp-2 cells; titer: 320, speckled 
nucleolar fluorescence), anti-double-stranded DNA 
(anti-dsDNA), anti-topoisomerase I antibodies (anti-Scl-
70) and anti-ribonucleoprotein antibodies (anti-RNP). 
Anti-SSA, anti-SSB, anti-Smith, and anti-Jo1 antibodies 
were negative. Anticardiolipin, anti-beta 2 glycoprotein 
and lupus anticoagulant were also negative. Both serum 
complement factor 3 and 4 were markedly depressed.
A chest radiograph revealed cardiomegaly with pulmonary 
congestion. ECG showed normal sinus rhythm. A Doppler 
study of the renal arteries did not reveal any evidence 
of renal artery stenosis. Both kidneys were within the 
normal size range and showed normal corticomedullary 
differentiation. An echocardiogram showed normal 
ejection fraction and minimal pericardial effusion without 
pulmonary hypertension. Gastroesophageal endoscopy 
and manometry proved pangastritis and discrete esophageal 
hypomotility. In addition, capillaroscopy revealed 
capillary dropout. Electromyogram revealed minimal pe
ripheral neuropathy.   Chestscan, after correction of fluid 
overload, showed discrete bilateral interstitial syndrome.
The patient was diagnosed as systemic lupus 
erythematosus and scleroderma overlap syndrome. 
Renal biopsy was performed and it showed diffuse and 
global membranous glomerulonephritis with active and 
chronic lesions (Activity Index: 6, Chronicity Index: 2), 
classified as lupus nephritis stage V+ IV-G [A(6)/C(2)] 
according to the ISN/RPS classification (Fig-1). Minimal 
inflammatory cellular infiltration of interstitial tissue was 
also seen. The extraglomerular renal vessels were normal 
(Fig-2). Immunofluorescence showed diffuse immune 
deposits of IgG, IgM, IgA, C3 and C1q.
Immunosuppression was started consisting of high-dose 
steroid (methylprednisolone 640 mg for 3 days followed 
by prednisolone 60 mg) and cyclophosphamide pulses 
(600 mg per month) along with diuretics, proton pump 
inhibitors, amlodipine and vitamin D3 supplements. 
Hydroxychroloquine was not used because of the visual 
field impairment. The clinical course was favourable with 
resumption of diuresis and improvement of renal function 
(creatinine level dropped  from 9.9 mg/dl to 6.0 mg/dl). 
However, at day 15 of   immunosuppression, the evolution 
was complicated by scleroderma renal crisis. Her blood 
pressure was 180/100 mm Hg and investigations showed 
thrombocytopenia (platelet count 75×103/L),  normocytic 
normochronic anemia with hemoglobin level of 7g/dl 
and the presence of schistocytes  in peripheral blood. 
Haptoglobin level was markedly depressed and Coomb’s 
test was negative. Her blood urea increased to 380 mg/
dL and creatinine to 8.8 mg/dl, serum sodium was 133 
meq/L, serum potassium was 5.9 meq/L, pH was 7.34 
and the bicarbonate level was 18 meq/L. 
Figure 1: Photomicrograph of the renal biopsy showing 
global endocapillary proliferation in a glomerulus. 
Periglomerular infiltrating cells were also noted 
(trichrome stain)
Figure 2: Photomicrograph of the renal biopsy showing 
normal extraglomerular renal vessels (trichrome stain)
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She was consequently started on hemodialysis. The 
patient was treated with perindopril 10 mg/day with rapid 
reduction of steroid dose (10 mg every 15 days reaching 
a dose of 10 mg/day). This was followed by correction of 
hemolysis and thrombocytopenia. Two months later, the 
patient was weaned from dialysis, but had chronic renal 
insufficiency with an estimated GFR of  25 ml/minute 
according to the Modification of Diet in Renal Disease 
(MDRD) formula.
Discussion
Patients with connective tissue disorders can often be 
classified into a specific disease according to certain 
criteria. Occasionally, patients may have features 
of overlap between more than one disease. Overlap 
syndromes usually include polymyositis and either SLE 
or scleroderma. Coexistence of SLE with scleroderma is 
rare [1, 6]. In a large series of SSc patients who developed 
one or more additional autoimmune diseases, only (0.8%) 
of patient had coexistence of SLE [7]. Shared clinical 
features between scleroderma and SLE such as arthritis, 
Raynaud’s phenomena, and renal involvement complicate 
the definition of leading conditions and dictate the use of 
additional diagnostic tools [8].
In patients with overlap syndromes, autoantibody 
profiles might be useful in diagnosis, predicting response 
to treatment and long-term prognosis [9]. Interesting 
serological findings were present in this  case with 
positive anti-Scl-70, anti-dsDNA, and anti-RNP. High 
titers of anti-Scl-70 are highly specific for SSc but are 
present only in 10-15% of SSc patients. The average 
prevalence of anti-Scl-70 in SLE is less than 5%, and 
it’s observed only in low titers [10]. Anti-dsDNA and 
anti-Sm antibodies are present in 70 and 30% of SLE 
patients respectively [1]. Anti RNP is more frequent 
(44%) in SSC/SLE overlap syndrome [10]. Coexistence 
of these antibodies is really rare [11].
Approximately 5 to 10% of patients with scleroderma 
develop renal crisis that mimics malignant hypertension, 
with rapidly progressive renal failure secondary 
to microvascular disease, vasospasm and tissue 
ischemia. Microangiopathic hemolytic anemia and 
thrombocytopenia can accompany scleroderma renal 
crisis [12]. Renal crisis may also occur in asclerodermic 
scleroderma [13]. Studies demonstrate that high levels 
of serum renin levels are associated with vasospasm 
and intrinsic renal vessel disease [12]. Hypertension 
(> 140/90 mmHg) in a scleroderma patient should be 
carefully evaluated because renal crisis is potentially 
reversible with appropriate management with angiotensin 
converting enzyme (ACE) inhibitors. 
Histopathologically, there is concentric edematous intimal 
thickening of interlobular arteries and fibrinoid arteriolar 
necrosis causing elevation of plasma renin level with onset 
or aggravation of hypertension and rapid deterioration of 
renal function as a result of ischemic glomerulopathy. 
Variable changes may be seen in the glomeruli, in some 
cases thickening of glomerular capillary walls with a 
double contour appearance on silver or periodic acid-
Schiff staining may be seen. Fibrinoid  necrosis may 
also be seen [14]. Crescents are very rare and those seen 
are invariably small. Interlobular arteries show intimal 
thickening which is mucinous or finely fibrous. The 
thickening results in considerable reduction of the lumen 
[12]. The occurrence of this SRC may therefore be conf
-used with other microangiopathies secondary to lupus, 
particularly antiphospholipid syndrome.
Lupus nephritis is a major cause of morbidity and 
mortality in patients with SLE. The general consensus 
is that 45-86% of lupus patients will develop clinically 
relevant nephritis at some time in the course of   their illness 
[15]. The initial clinical presentation of lupus nephritis 
ranges from asymptomatic proteinuria discovered on 
routine urinalysis to the nephrotic syndrome with or 
without renal impairment. Histologic examination of a 
renal-biopsy specimen is a pivotal step in confirming the 
diagnosis and guiding therapy [16]. The histopathological 
patterns of lupus nephritis have been classified by the 
World Health Organization and, more recently, by the 
International Society of Nephrology/ Renal Pathology 
Society (ISN/RPS) [17]. Immunosuppressive therapy 
consists of glucocorticoids combined with a cytotoxic 
drug (cyclophosphamide, mycophenolate mofetil (MMF)) 
to achieve a prompt response [15]. In SSc/SLE patients 
who develop renal failure and hypertension, it is essential 
to distinguish between lupus nephritis and scleroderma 
renal crisis because the treatment is completely different 
[13]. Almost all current treatment regimens for lupus 
nephritis include steroids, usually pulses of high doses 
at induction and then tapering doses of oral steroids. 
However, SRC has been associated with the use of high 
doses or recently introduced corticoisteroids.
The concern that corticosteroid use may exacerbate the 
clinical manifestations of SSc has been longstanding 
[18]. A case control study retrospectively reviewed 
the relationship of SRC to corticosteroid use in the six 
months preceding the onset of SRC [19]. This study 
suggested that  recent  use of prednisone in dosages 
exceeding 15 mg daily was significantly associated with 
the subsequent onset of SRC, whereas recent use of 
low-dose steroids (less than 15 mg daily) or continuous 
use of steroids for six months was not associated with 
increased risk of SRC.
revealed pulmonary crackles and tightness of the 
skin over the face and hands. The rest of examination 
was normal.
Her urine dipstick examination revealed two crosses of 
protein and blood. 24-hour urine protein was 2 g/day. 
The blood urea and serum creatinine levels were 180 
mg/dL and 9.9 mg/dL respectively, sodium 137 meq/L 
and potassium  4.8 meq/L. Her complete blood count 
revealed a hemoglobin of 9 g/dl, a platelet count of 
272×109/L, and white blood cell count of 3000×109/L 
with 700×109/L lymphocytes. On admission she had 
no evidence of hemolysis with haptoglobin level of 1.6 
g/L, LDH 145 units/L, total bilirubin 0.5 mg/dL and 
alanine transaminase 10 units/L. Her serum albumin 
was 3.1 mg/dL. She was hepatitis B surface antigen and 
anti-HCV antibody negative.
Autoantibody screening at that time detected elevated 
titers of antinuclear antibodies (using indirect immu-
nofluorescence on HEp-2 cells; titer: 320, speckled 
nucleolar fluorescence), anti-double-stranded DNA 
(anti-dsDNA), anti-topoisomerase I antibodies (anti-Scl-
70) and anti-ribonucleoprotein antibodies (anti-RNP). 
Anti-SSA, anti-SSB, anti-Smith, and anti-Jo1 antibodies 
were negative. Anticardiolipin, anti-beta 2 glycoprotein 
and lupus anticoagulant were also negative. Both serum 
complement factor 3 and 4 were markedly depressed.
A chest radiograph revealed cardiomegaly with pulmonary 
congestion. ECG showed normal sinus rhythm. A Doppler 
study of the renal arteries did not reveal any evidence 
of renal artery stenosis. Both kidneys were within the 
normal size range and showed normal corticomedullary 
differentiation. An echocardiogram showed normal 
ejection fraction and minimal pericardial effusion without 
pulmonary hypertension. Gastroesophageal endoscopy 
and manometry proved pangastritis and discrete esophageal 
hypomotility. In addition, capillaroscopy revealed 
capillary dropout. Electromyogram revealed minimal pe
ripheral neuropathy.   Chestscan, after correction of fluid 
overload, showed discrete bilateral interstitial syndrome.
The patient was diagnosed as systemic lupus 
erythematosus and scleroderma overlap syndrome. 
Renal biopsy was performed and it showed diffuse and 
global membranous glomerulonephritis with active and 
chronic lesions (Activity Index: 6, Chronicity Index: 2), 
classified as lupus nephritis stage V+ IV-G [A(6)/C(2)] 
according to the ISN/RPS classification (Fig-1). Minimal 
inflammatory cellular infiltration of interstitial tissue was 
also seen. The extraglomerular renal vessels were normal 
(Fig-2). Immunofluorescence showed diffuse immune 
deposits of IgG, IgM, IgA, C3 and C1q.
Immunosuppression was started consisting of high-dose 
steroid (methylprednisolone 640 mg for 3 days followed 
by prednisolone 60 mg) and cyclophosphamide pulses 
(600 mg per month) along with diuretics, proton pump 
inhibitors, amlodipine and vitamin D3 supplements. 
Hydroxychroloquine was not used because of the visual 
field impairment. The clinical course was favourable with 
resumption of diuresis and improvement of renal function 
(creatinine level dropped  from 9.9 mg/dl to 6.0 mg/dl). 
However, at day 15 of   immunosuppression, the evolution 
was complicated by scleroderma renal crisis. Her blood 
pressure was 180/100 mm Hg and investigations showed 
thrombocytopenia (platelet count 75×103/L),  normocytic 
normochronic anemia with hemoglobin level of 7g/dl 
and the presence of schistocytes  in peripheral blood. 
Haptoglobin level was markedly depressed and Coomb’s 
test was negative. Her blood urea increased to 380 mg/
dL and creatinine to 8.8 mg/dl, serum sodium was 133 
meq/L, serum potassium was 5.9 meq/L, pH was 7.34 
and the bicarbonate level was 18 meq/L. 
Figure 1: Photomicrograph of the renal biopsy showing 
global endocapillary proliferation in a glomerulus. 
Periglomerular infiltrating cells were also noted 
(trichrome stain)
Figure 2: Photomicrograph of the renal biopsy showing 
normal extraglomerular renal vessels (trichrome stain)
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Trang et al have found in a systematic review that 2% 
of all SSc patients and 4% of early diffuse scleroderma 
patients treated with CS developed SRC [5]. Anemia, 
new cardiac events (e.g. pericardial effusion or 
congestive heart failure), diffuse skin thickening, rapidly 
progressive skin thickening, large joint contractures, SSc 
disease duration more than 4 years, and the presence of 
anti-RNA polymerase III antibody may also increase the 
risk of RCS. Urinary abnormalities and elevations of 
serum creatinine or plasma renin preceding the onset of 
SRC have not been shown to predict SRC [20].
Concomitant lupus nephritis and SSc overlap syndrome 
may limit the use of high steroid doses in SLE and may 
advocate early use of cytotoxic drugs and other biological 
therapies. Reduction in steroid dose may be achieved 
with aggressive immunosuppression including novel 
biological therapies. Clinical trials and case studies have 
reported the efficacy and safety of rituximab and MMF 
in SLE. Rituximab may also significantly improved lung 
function tests and skin score one year after treatment 
in patients with SSC. It seems that in SSc/SLE overlap 
these therapies could be attractive for both conditions 
yet there are no data in the literature [8]. Also, possible 
exacerbation of SLE may limit the use of anti-TNFα 
agents in SSc/SLE overlap [21].
In this case the importance of  corticosteroids in 
the treatment of  lupus nephritis and the low risk 
of occurrence of renal crisis (2%) prompted us to use high 
doses of CS. However, after the onset of scleroderma 
renal crisis, the rapid reduction in CS dose and the use 
of angiotensin converting enzyme inhibitors together 
with cyclophosphamide improved the prognosis in this 
particular patient.
Conclusion
This observation underlines the importance of analyzing 
the benefits and risks of steroid treatment when lupus 
nephritis is associated with scleroderma in SLE/SSc 
overlap syndrome.
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Trang et al have found in a systematic review that 2% 
of all SSc patients and 4% of early diffuse scleroderma 
patients treated with CS developed SRC [5]. Anemia, 
new cardiac events (e.g. pericardial effusion or 
congestive heart failure), diffuse skin thickening, rapidly 
progressive skin thickening, large joint contractures, SSc 
disease duration more than 4 years, and the presence of 
anti-RNA polymerase III antibody may also increase the 
risk of RCS. Urinary abnormalities and elevations of 
serum creatinine or plasma renin preceding the onset of 
SRC have not been shown to predict SRC [20].
Concomitant lupus nephritis and SSc overlap syndrome 
may limit the use of high steroid doses in SLE and may 
advocate early use of cytotoxic drugs and other biological 
therapies. Reduction in steroid dose may be achieved 
with aggressive immunosuppression including novel 
biological therapies. Clinical trials and case studies have 
reported the efficacy and safety of rituximab and MMF 
in SLE. Rituximab may also significantly improved lung 
function tests and skin score one year after treatment 
in patients with SSC. It seems that in SSc/SLE overlap 
these therapies could be attractive for both conditions 
yet there are no data in the literature [8]. Also, possible 
exacerbation of SLE may limit the use of anti-TNFα 
agents in SSc/SLE overlap [21].
In this case the importance of  corticosteroids in 
the treatment of  lupus nephritis and the low risk 
of occurrence of renal crisis (2%) prompted us to use high 
doses of CS. However, after the onset of scleroderma 
renal crisis, the rapid reduction in CS dose and the use 
of angiotensin converting enzyme inhibitors together 
with cyclophosphamide improved the prognosis in this 
particular patient.
Conclusion
This observation underlines the importance of analyzing 
the benefits and risks of steroid treatment when lupus 
nephritis is associated with scleroderma in SLE/SSc 
overlap syndrome.
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